Transformation of a new scientific idea into a new oncology-based drug requires a tremendous amount of time, effort and investment. The […]
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Patenting the Microbiome – Part 2: Microbiome IP Panel, 2017 BIO Convention Read Post »
This is a guest post from Michael D. Hooven, President & CEO, Enable Injections Inc. The oxpecker perches on the backs
Solving the problem of biologic delivery: Large volume wearable injectors Read Post »
Hermann A. M. Mucke*, H. M. Pharma Consultancy, Wien, Austria A Multimodal Approach to the Re-development of Drugs Drug repositioning—the investigation, development and use of active pharmaceutical ingredients for a…
The post Drug Repositioning in the …
Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory Read Post »
This is a guest post from Craig Stropkay. Craig is Director and Life Science Consultant at KOLgroups, LLC Reach for the
This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the
3 Tips for Finding the Right Talent for Your Biotech Startup Read Post »
This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Biotech in Countries Starting with “I” – Part 11: Italy (secondo) Read Post »
The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries
Which drug makers do a good job getting poor patients access to their medicines? Read Post »
This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below.
Addressing the Challenges of Pharmaceutical Distribution in International Markets Read Post »